Hancock Jaffe Laboratories Inc

Hancock Jaffe Laboratories Inc Stock Forecast & Price Prediction

Live Hancock Jaffe Laboratories Inc Stock (HJLI) Price
$3.40

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$3.40

P/E Ratio

-0.45

Volume Traded Today

$44,567

Dividend

Dividends not available for HJLI

52 Week High/low

6.97/3.01

Hancock Jaffe Laboratories Inc Market Cap

$32.4M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $HJLI ๐Ÿ›‘

Before you buy HJLI you'll want to see this list of ten stocks that have huge potential. Want to see if HJLI made the cut? Enter your email below

HJLI Summary

The Hancock Jaffe Laboratories Inc (HJLI) share price is expected to decrease by 100% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered HJLI. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for HJLI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

HJLI Analyst Ratings

About 0 Wall Street analysts have assignedHJLI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Hancock Jaffe Laboratories Inc to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HJLI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

HJLI stock forecast by analyst

These are the latest 20 analyst ratings of HJLI.

Analyst/Firm

Rating

Price Target

Change

Date

Data Not Found!

HJLI Company Information

HJLI
Hancock Jaffe Laboratories Inc (HJLI)

When did it IPO

2018

Staff Count

0

Country

United States

Sector/Industry

/

CEO

Market Cap

$32.4M

Hancock Jaffe Laboratories Inc (HJLI) Financial Data

In 2023, HJLI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HJLI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

$0

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year

Revenue From 2023

N/A

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -103.5%
  • Return on equity TTM 14.9%
  • Profit Margin 0.0%
  • Book Value Per Share -7.94%
  • Market capitalisation $32.4M
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • Revenue for 2023 N/A
  • EPS this year (TTM) $-7.54

Hancock Jaffe Laboratories Inc (HJLI) Latest News

News Image

Wed, 22 Sep 2021

Sentiment - POSITIVE

Source - Benzinga

Summary - Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will rebrand as enVVeno Medical Corporation (ticker: NVNO) on October 1, focusing exclusively on the VenoValve for venous disease treatment.

Why It Matters - The rebranding and strategic focus on the VenoValve may enhance investor confidence, potentially driving stock performance and attracting new interest in the company's innovative approach to venous disease.

News Image

Fri, 24 Sep 2021

Sentiment - NEUTRAL

Source - Accesswire

Summary - Hancock Jaffe Laboratories CEO Robert Berman will participate in a webinar on September 27, 2021, at 1:00 PM ET, hosted by Ladenburg Thalmann, focusing on venous disease treatments.

Why It Matters - The webinar could provide insights into Hancock Jaffe's strategies and innovations, influencing investor sentiment and potential stock performance.

News Image

Tue, 21 Sep 2021

Sentiment - NEUTRAL

Source - Accesswire

Summary - Hancock Jaffe will rebrand as enVVeno Medical Corporation (NASDAQ: NVNO) on October 1, 2021, focusing on venous disease and advancing the VenoValveยฎ. A second product is expected in mid-2022.

Why It Matters - The rebranding to enVVeno Medical Corporation and focus on venous disease could attract investors seeking growth in a specialized medical sector, potentially increasing stock value and market interest.

News Image

Wed, 15 Sep 2021

Sentiment - NEUTRAL

Source - Accesswire

Summary - Hancock Jaffe Laboratories, Inc. will hold a corporate update conference call with a live video webcast on September 21, 2021, at 4:30 p.m. ET.

Why It Matters - The conference call indicates potential updates on company performance and product developments, which can influence stock prices and investor sentiment for Hancock Jaffe Laboratories.

News Image

Tue, 07 Sep 2021

Sentiment - NEUTRAL

Source - Accesswire

Summary - Hancock Jaffe Laboratories, Inc. announced a $20 million registered direct offering, selling 2,540,650 shares at $7.8720 each to a fund managed by Perceptive Advisors.

Why It Matters - Hancock Jaffe's $20 million capital raise enhances liquidity for growth and innovation, signaling confidence from investors like Perceptive Advisors, which may positively influence stock performance.

News Image

Wed, 08 Sep 2021

Sentiment - POSITIVE

Source - Seeking Alpha

Summary - Hancock Jaffe Laboratories, focused on bioprosthetics for cardiovascular diseases, received IDE approval in April 2021 to start a pivotal trial for its VenoValve product in the U.S.

Why It Matters - Hancock Jaffe's IDE approval for VenoValve indicates potential market entry and revenue growth, signaling a promising advancement in cardiovascular treatments that could enhance investor confidence.

...

HJLI Frequently asked questions

The highest forecasted price for HJLI is $ from at .

The lowest forecasted price for HJLI is $ from from

The HJLI analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.